Literature DB >> 9407354

Partial hepatic resection for hepatocellular carcinoma.

M F Chen1, L B Jeng.   

Abstract

This review summarizes the efficacy of the most common therapeutic option for hepatocellular carcinoma (HCC), partial hepatic resection, taking into account not only its antitumoural effect, but also its consequences on survival. Partial hepatic resection results in 5 year survival rates as high as 45% in more favourable subgroups having: small tumours, well-differentiated tumours, unifocal tumours, a lack of vascular invasions, an absence of cirrhosis, and the fibrolamellar variant. Resection has been limited primarily by low resectability rates and recurrent disease. However, surgical resection in the form of partial hepatectomy is the preferred treatment for HCC. The early detection of tumours by screening high-risk populations is crucial. During the 12 year period between 1983 and 1994, hepatic resections were carried out in 382 patients with HCC. One hundred and fifty-three (40%) had HCC smaller than 5 cm in diameter. There were 294 male and 88 female patients, with an average age of 52.3 years. Among them, 45% had liver cirrhosis and 73% were positive for hepatitis B surface antigen. Two hundred and eighteen (57%) were positive for hepatitis C virus circulating antibodies (since 1991). Operative mortality was 3.9%. The overall survival rates at 1, 3 and 5 years were 71, 52 and 46%, respectively. Sex, cirrhosis, Child's staging, surgical procedure, blood loss, pathological pattern, presence of capsule, surgical margin and DNA ploidy appeared to be factors not related to prognosis. However, alpha-fetoprotein level, size (whether less than or greater than 5 cm), and vascular invasion were factors which significantly affect survival.

Entities:  

Mesh:

Year:  1997        PMID: 9407354     DOI: 10.1111/j.1440-1746.1997.tb00517.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Extent of liver resection modulates the activation of transcription factors and the production of cytokines involved in liver regeneration.

Authors:  Jan-Peter Sowa; Jan Best; Tamas Benko; Maximillian Bockhorn; Yanli Gu; Eva-Maria Niehues; Agnieska Bucchi; Eva-Maria Benedetto-Castro; Guido Gerken; Ursula Rauen; Jorg-Friedrich Schlaak
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

2.  Hepatic resection for hepatocellular carcinoma with obstructive jaundice due to biliary tumor thrombi.

Authors:  Chun-Nan Yeh; Yi-Yin Jan; Wei-Chen Lee; Miin-Fu Chen
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

3.  Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan.

Authors:  Miin-Fu Chen; Long-Bin Jeng; Wei-Chen Lee
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

4.  Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma.

Authors:  Kun-Ming Chan; Ming-Chin Yu; Ting-Jung Wu; Chen-Fang Lee; Tse-Ching Chen; Wei-Chen Lee; Miin-Fu Chen
Journal:  World J Gastroenterol       Date:  2009-11-21       Impact factor: 5.742

Review 5.  Liver-directed therapies for patients with primary liver cancer and hepatic metastases.

Authors:  Cletus A Arciero; Elin R Sigurdson
Journal:  Curr Treat Options Oncol       Date:  2006-09

6.  Giant pedunculated hepatocellular carcinoma with hemangioma mimicking intestinal obstruction.

Authors:  Theodore Karatzas; Anastasios Smirnis; Dimitrios Dimitroulis; Dimitrios Patsouras; Kostantinos Evaggelou; Stylianos Kykalos; Gregory Kouraklis
Journal:  BMC Gastroenterol       Date:  2011-09-22       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.